Budesonide (Entocort) is effective for the treatment of collagenous colitis.
Dr Miehlke assessed the long-term outcome of patients after induction of clinical remission by budesonide treatment.
The investigative team enrolled 51 patients with chronic diarrhoea and histologically proven collagenous colitis.
The team conducted a randomized, placebo-controlled crossover trial using budesonide 9 mg daily for 6 weeks.
Patients in clinical remission after either initial or crossover budesonide treatment were followed using standardized questionnaires.
Clinical relapse was defined as 5 or more loose stools/day for at least 4 consecutive days.
The investigators noted that a total of 85% achieved clinical remission.
|Budesonide achieved clinical response in relapse in 80%|
|Alimentary Pharmacology & Therapeutics|
During a median follow-up of 16 months, clinical relapse occurred in 61% patients, after a median time of 2 weeks.
Patient age of less than 60 years was identified as a significant risk factor for clinical relapse.
The investigators found that budesonide was used for treatment of clinical relapse in 80% of patients achieving clinical response in all of them.
Dr Miehlke's team concluded, “Budesonide is effective in the treatment of collagenous colitis.”
“Clinical relapses may occur in a considerable number of patients, particularly in those under 60 years.
“Treatment of clinical relapse with budesonide appears to be an effective option.”